1. Home
  2. WLDN vs KALV Comparison

WLDN vs KALV Comparison

Compare WLDN & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WLDN
  • KALV
  • Stock Information
  • Founded
  • WLDN 1964
  • KALV N/A
  • Country
  • WLDN United States
  • KALV United States
  • Employees
  • WLDN N/A
  • KALV N/A
  • Industry
  • WLDN Military/Government/Technical
  • KALV Biotechnology: Pharmaceutical Preparations
  • Sector
  • WLDN Consumer Discretionary
  • KALV Health Care
  • Exchange
  • WLDN Nasdaq
  • KALV Nasdaq
  • Market Cap
  • WLDN 826.2M
  • KALV 725.3M
  • IPO Year
  • WLDN 2006
  • KALV N/A
  • Fundamental
  • Price
  • WLDN $82.04
  • KALV $14.58
  • Analyst Decision
  • WLDN Strong Buy
  • KALV Strong Buy
  • Analyst Count
  • WLDN 2
  • KALV 9
  • Target Price
  • WLDN $49.00
  • KALV $26.29
  • AVG Volume (30 Days)
  • WLDN 389.2K
  • KALV 1.9M
  • Earning Date
  • WLDN 08-07-2025
  • KALV 07-10-2025
  • Dividend Yield
  • WLDN N/A
  • KALV N/A
  • EPS Growth
  • WLDN 79.39
  • KALV N/A
  • EPS
  • WLDN 1.68
  • KALV N/A
  • Revenue
  • WLDN $595,695,000.00
  • KALV N/A
  • Revenue This Year
  • WLDN N/A
  • KALV N/A
  • Revenue Next Year
  • WLDN $9.94
  • KALV $347.19
  • P/E Ratio
  • WLDN $48.77
  • KALV N/A
  • Revenue Growth
  • WLDN 12.40
  • KALV N/A
  • 52 Week Low
  • WLDN $30.43
  • KALV $7.30
  • 52 Week High
  • WLDN $82.99
  • KALV $16.32
  • Technical
  • Relative Strength Index (RSI)
  • WLDN 87.30
  • KALV 52.02
  • Support Level
  • WLDN $76.00
  • KALV $15.20
  • Resistance Level
  • WLDN $81.17
  • KALV $16.09
  • Average True Range (ATR)
  • WLDN 2.89
  • KALV 0.89
  • MACD
  • WLDN 0.07
  • KALV -0.03
  • Stochastic Oscillator
  • WLDN 93.03
  • KALV 29.55

About WLDN Willdan Group Inc.

Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: